Welcome to the Oncomine Blog

UAB Study Evaluates the Oncomine Myeloid Research Assay GX on the Genexus System

Performance of the Oncomine Myeloid Research Assay GX


Craig Mackinnon, MD, PhD, Director of Genomic Diagnostics and Bioinformatics and Professor of the Department of Pathology, and his team at the University of Alabama, Birmingham (UAB) conducted a study evaluating the performance of the Oncomine Myeloid Research Assay GX on the Genexus System with samples containing mutations in key genes associated with various myeloid research disorders.

Difficult-to-detect targets such as FLT3, CALR, and CEBPA were included. Performance was assessed against the well-established Ion Torrent™ Oncomine™ Myeloid Research Assay on the Ion GeneStudio S5 System.


Performance of the Oncomine Myeloid Research Assay GX

Dr. Mackinnon advises anyone interested in setting up a next-generation sequencing (NGS) panel in a molecular oncology research lab to consider a platform that can accommodate a wide range of specimens, including those that are small and/or low quantity.

Sequencing challenges are compounded by the diversity of frequently co-existing complex variants underlying somatic changes present in many samples. Consequently, robust NGS assays capable of identifying single-nucleotide variants (SNV), small indels, and fusions in a single workflow are required.

Table 1: A range of commonly mutated genes in myeloid research malignancies.


Table 2: Results show high concordance between the Genexus System and the GeneStudio S5 System.


Summary of the Evaluation

  • The Oncomine Myeloid Research Assay GX achieved 100% concordance with Myeloid Research Assay on the GeneStudio S5 System

  • The Genexus System demonstrated comparable sensitivity for gene detection, a wide variety of challenging variants, including difficult to detect targets—FLT3-ITD, CALR, CEBPA.



In their quest to optimize their lab operations, UAB evaluated the Oncomine Myeloid Assay GX and the Genexus System. Dr. Mackinnon concluded that the Genexus System and its assays offer several key advantages over previous NGS platforms:

  • Reduces overhead substantially due to lower reagent costs, less tech hands-on time, and reporting.
  • Delivers significantly faster turnaround times (2 day) with minimal hands-on-time.
  • Detects challenging variants like indels and targets with G-C rich DNA
  • Enables lower DNA and RNA input than other assays, permitting testing of a wider range of samples—an important consideration when sequencing FFPE samples.

If you would like to learn more about this study, Watch Dr. Mackinnon's Presentation

Share this article
Thermo Fisher Scientific Staff
Article by:

Thermo Fisher Scientific Staff

RET Aberrations and EGFR Exon 20 Insertions Testing in the Complex NSCLC Biomarker Landscape

In his recent OncomineWorld webinar, Dr. Fernando López-Ríos, MD, PhD (Department of Pathology, 12 de Octubre” University Hospital, Madrid, Spain)described the latest developments and challenges in the complex NSCLC biomarker landscape, explaining...

Collaborating Early to Advance Precision Medicine – A Look Inside Thermo Fisher’s CDx Program with Garret Hampton

Companion diagnostic (CDx) tests are powerful tools in precision medicine and help advance more widespread use of targeted cancer therapies. The U.S. Food Drug Administration (FDA) defines CDx as “essential for the therapeutic product’s safe and...

University of Munich Evaluates the Oncomine Comprehensive Plus Assay for HRD Detection

Our OncomineWorld event in 2021 brought thousands of professionals together from around the world to advance our understanding of next-generation sequencing (NGS) in precision oncology research. By enabling simultaneous, comprehensive genomic...